Skip to content

Zymeworks ZYME Available-for-Sale Debt Securities - Amortized Cost

Available-for-Sale Debt Securities - Amortized Cost at other companies

Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$586.4M-6.6%
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$607.54M+349%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$86.7M-58.6%
iRhythm Holdings, Inc.
 logo
iRhythm Holdings, Inc. IRTC
$455.35M+42.2%
Amgen logo
AmgenAMGN
Spyre Therapeutics, Inc. logo
Spyre Therapeutics, Inc.SYRE

Other financials

Income statement

See full
Revenue$2.4M-91.1%
Operating income-$47.1M-84.0%
Net income-$44.2M-95.1%
EPS (diluted)-$0.59-96.7%

Balance sheet

See full
Cash & equivalents$244.3M+221%
Total debt$17.0M-7.7%
Total equity$163.6M-49.7%
Total assets$478.2M+12.4%

Cash flow

See full
Operating cash flow-$45.7M-1,242%
CapEx$216.0K+1,250%
Free cash flow-$45.9M-1,242%

Valuation

See full
Market cap$1.79B+125%

Profitability

See full
Operating margin-140.4%+7.3pp
Net margin-126.3%+5.0pp
FCF margin-94.8%+15.5pp

Returns & leverage

See full
Return on equity-42%+29.2pp
Debt / equity0.1×0.0×
Current ratio10.8×+6.1×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost.

The official record: Zymeworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zymeworks's available-for-sale debt securities - amortized cost.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zymeworks's available-for-sale debt securities - amortized cost?
Zymeworks (ZYME) reported available-for-sale debt securities - amortized cost of $120.41M in Q1 2026.
How has Zymeworks's available-for-sale debt securities - amortized cost changed year-over-year?
Zymeworks's available-for-sale debt securities - amortized cost decreased by 36.3% year-over-year, from $188.94M to $120.41M.
What is the long-term trend for Zymeworks's available-for-sale debt securities - amortized cost?
Over 2 years (2023 to 2025), Zymeworks's available-for-sale debt securities - amortized cost has grown at a -6.9% compound annual growth rate (CAGR), from $216.38M to $187.46M.
What does available-for-sale debt securities - amortized cost mean?
This is the cost basis of debt securities classified as available-for-sale, adjusted for amortization of premiums or discounts. It represents the value of the investment portfolio before accounting for current market price fluctuations. This provides a baseline for evaluating the performance of the company's liquid investment strategy.